XML 52 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Statements of Cash Flows (Brooklyn ImmunoTherapeutics, LLC) - USD ($)
 2 Months Ended 3 Months Ended 9 Months Ended 10 Months Ended 12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Nov. 05, 2018
Dec. 31, 2019
Dec. 31, 2018
Cash Flows from Operating Activities                  
Net loss     $ (1,481,000) $ (351,000) $ (4,722,000) $ (754,000)   $ (2,047,000) $ (259,000)
Adjustments to reconcile net loss to net cash used in operating activities:                  
Depreciation and amortization     26,000 88,000 189,000 273,000   360,000 315,000
Equity compensation     53,000 63,000 135,000 172,000   206,000 443,000
Change in operating assets and liabilities:                  
Accounts payable and accrued expenses         (1,405,000) (196,000)   669,000 (186,000)
Other liabilities         (291,000) (141,000)   108,000 41,000
Net cash (used in) provided by operating activities         (3,280,000) 1,761,000   2,744,000 1,365,000
Cash Flows from Investing Activities:                  
Net Cash Provided by (Used in) Investing Activities         (194,000) (964,000)   (1,065,000) (1,579,000)
Cash Flows from Financing Activities:                  
Net cash provided by (used in) financing activities         1,765,000 (826,000)   (1,098,000) (303,000)
Net decrease in cash, cash equivalents and restricted cash         (1,699,000) (2,000)   623,000 (592,000)
Cash, cash equivalents and restricted cash at beginning of period         3,409,000 2,786,000 $ 3,378,000 2,786,000 3,378,000
Cash, cash equivalents and restricted cash at end of period $ 2,786,000 $ 2,786,000 1,710,000 2,784,000 1,710,000 2,784,000   3,409,000 2,786,000
Cash and Restricted Cash consisted of the following:                  
Restricted cash 50,000 50,000 51,000 51,000   50,000 50,000
Supplemental Disclosures of Cash Flow Information:                  
Cash paid during the period for : Interest         86,000 195,000   246,000 336,000
Cash paid during the period for : Income taxes         23,000 26,000   26,000 17,000
Brooklyn Immunotherapeutics, LLC [Member]                  
Cash Flows from Operating Activities                  
Net loss         (5,072,803) (6,134,389)   8,937,054  
Adjustments to reconcile net loss to net cash used in operating activities:                  
Depreciation and amortization         72,909 7,917      
Equity compensation         68,202 68,674      
Loss on operating sublease              
Change in operating assets and liabilities:                  
Prepaid expenses and other current assets         (69,240) (62,240)      
Security deposits         (84,914)      
Accounts payable and accrued expenses         (1,392,925) (2,134,303)      
Lease liability         (2,356)      
Other liabilities         17,842 52,254      
Total adjustments         (1,390,482) (2,067,698)      
Net cash (used in) provided by operating activities         (6,463,285) (8,202,087)   9,800,291 18,436,717
Cash Flows from Investing Activities:                  
Patent costs              
Purchase of property and equipment         (26,177) (8,756)      
Purchase of leasehold improvements         (100,000)      
Purchase of IRX - cash and restricted cash acquired              
Net Cash Provided by (Used in) Investing Activities         (26,177) (108,756)      
Cash Flows from Financing Activities:                  
Proceeds from loans payable         309,905      
Proceeds from loans payable, related parties              
Proceeds from convertible debt              
Proceeds from investor deposits           437,500  
Proceeds from the collection of subscriptions receivable         275,000 850,000   850,000  
Proceeds from sale of members' equity         3,858,750 7,395,750   7,808,250  
Net cash provided by (used in) financing activities         4,443,655 8,245,750      
Net decrease in cash, cash equivalents and restricted cash         (2,045,807) (65,093)      
Cash, cash equivalents and restricted cash at beginning of period         5,100,819 6,411,431   6,411,431  
Cash, cash equivalents and restricted cash at end of period 6,411,431 6,411,431 3,055,012 6,346,338 3,055,012 6,346,338   5,100,819 6,411,431
Cash and Restricted Cash consisted of the following:                  
Cash 6,325,431 6,325,431 3,055,012 6,260,338 3,055,012 6,260,338   5,014,819 6,325,431
Restricted cash 86,000 86,000 86,000 86,000   86,000 86,000
Cash and Restricted Cash Equivalents     $ 3,055,012 $ 6,346,338 3,055,012 6,346,338      
Supplemental Disclosures of Cash Flow Information:                  
Cash paid during the period for : Interest              
Cash paid during the period for : Income taxes              
Brooklyn Immunotherapeutics, LLC [Member] | Successor [Member]                  
Cash Flows from Operating Activities                  
Net loss   (2,004,472)           (8,937,054)  
Adjustments to reconcile net loss to net cash used in operating activities:                  
Depreciation and amortization   1,498           20,407  
Equity compensation 20,248 20,248           91,689  
Loss on operating sublease             103,350  
Change in operating assets and liabilities:                  
Prepaid expenses and other current assets             (66,670)  
Security deposits             76,155  
Accounts payable and accrued expenses   (168,298)           (1,087,874)  
Lease liability             (294)  
Other liabilities              
Total adjustments   (146,552)           (863,237)  
Net cash (used in) provided by operating activities   (2,151,024)           (9,800,291)  
Cash Flows from Investing Activities:                  
Patent costs              
Purchase of property and equipment             (606,071)  
Purchase of IRX - cash and restricted cash acquired   336,296            
Net Cash Provided by (Used in) Investing Activities   336,296           (606,071)  
Cash Flows from Financing Activities:                  
Proceeds from loans payable              
Proceeds from loans payable, related parties              
Proceeds from convertible debt              
Proceeds from investor deposits             437,500  
Proceeds from the collection of subscriptions receivable             850,000  
Proceeds from sale of members' equity   1,744,154           7,808,250  
Net cash provided by (used in) financing activities   1,744,154           9,095,750  
Net decrease in cash, cash equivalents and restricted cash   (70,574)           (1,310,612)  
Cash, cash equivalents and restricted cash at beginning of period   6,482,005     $ 5,100,819 $ 6,411,431   6,411,431  
Cash, cash equivalents and restricted cash at end of period 6,411,431 6,411,431           5,100,819 6,411,431
Cash and Restricted Cash consisted of the following:                  
Cash 6,325,431 6,325,431           5,014,819 6,325,431
Restricted cash 86,000 86,000           86,000 86,000
Cash and Restricted Cash Equivalents 6,411,431 6,411,431           5,100,819 6,411,431
Supplemental Disclosures of Cash Flow Information:                  
Cash paid during the period for : Interest              
Cash paid during the period for : Income taxes              
Non-cash investing and financing activities:                  
Investor deposits for sale of members' equity             410,512  
Conversion of loans payable and interest into members' equity   1,516,346            
Exchange of Series A, B and C preferred stock for common stock              
Assets acquired and liabilities assumed:                  
Cash acquired   336,296            
Prepaid expenses and other current assets   19,998            
Security deposits and other assets   379,331            
Goodwill   2,043,747            
In-process R&D   6,860,000            
Property and equipment   69,597            
Accounts payable and accrued expenses   (4,528,969)            
Loans payable, related parties   (1,500,000)            
Loans payable   (410,000)            
Total purchase price   3,270,000            
Purchase price consisted of:                  
Members' equity issued to acquire the asset and liabilities of IRX   2,400,000            
Contingent consideration   870,000            
Total purchase price   $ 3,270,000            
Brooklyn Immunotherapeutics, LLC [Member] | Predecessor [Member]                  
Cash Flows from Operating Activities                  
Net loss             (16,098,602)    
Adjustments to reconcile net loss to net cash used in operating activities:                  
Depreciation and amortization             136,314    
Equity compensation                
Loss on operating sublease                
Change in operating assets and liabilities:                  
Prepaid expenses and other current assets             (69,099)    
Security deposits             8,001    
Accounts payable and accrued expenses             (300,034)    
Lease liability                
Other liabilities             37,727    
Total adjustments             (187,091)    
Net cash (used in) provided by operating activities             (16,285,693)   16,285,693
Cash Flows from Investing Activities:                  
Patent costs             (172,196)    
Purchase of property and equipment             (76,485)    
Purchase of IRX - cash and restricted cash acquired                
Net Cash Provided by (Used in) Investing Activities             (248,681)    
Cash Flows from Financing Activities:                  
Proceeds from loans payable             3,394,226    
Proceeds from loans payable, related parties             1,500,000    
Proceeds from convertible debt             11,803,321    
Proceeds from investor deposits                
Proceeds from the collection of subscriptions receivable                
Proceeds from sale of members' equity                
Net cash provided by (used in) financing activities             16,697,547    
Net decrease in cash, cash equivalents and restricted cash             163,173    
Cash, cash equivalents and restricted cash at beginning of period $ 336,296           173,123   $ 173,123
Cash, cash equivalents and restricted cash at end of period             336,296    
Cash and Restricted Cash consisted of the following:                  
Cash             250,296    
Restricted cash             86,000    
Cash and Restricted Cash Equivalents             336,296    
Supplemental Disclosures of Cash Flow Information:                  
Cash paid during the period for : Interest                
Cash paid during the period for : Income taxes                
Non-cash investing and financing activities:                  
Investor deposits for sale of members' equity                
Conversion of loans payable and interest into members' equity                
Exchange of Series A, B and C preferred stock for common stock             106,560,811    
Assets acquired and liabilities assumed:                  
Cash acquired                
Prepaid expenses and other current assets                
Security deposits and other assets                
Goodwill                
In-process R&D                
Property and equipment                
Accounts payable and accrued expenses                
Loans payable, related parties                
Loans payable                
Total purchase price                
Purchase price consisted of:                  
Members' equity issued to acquire the asset and liabilities of IRX                
Contingent consideration                
Total purchase price